1-2 of 2
Ali Fattaey, PhD
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

The Combination of Venetoclax and CUDC-907 Exhibits Synergistic Activity in Venetoclax-Refractory DLBCL

Kaiming Sun, PhD, Ruzanna Atoyan, MD, Mylissa A Borek, MS, Steven Dellarocca, MS, Garrett Rhyasen, PhD, Ali Fattaey, PhD, David P Tuck, MD
Journal: Blood
Blood (2016) 128 (22): 4184.
https://doi.org/10.1182/blood.V128.22.4184.4184
Published: 2016
Journal Articles

A First-In-Man Phase 1 Study Of CUDC-907, a First-In-Class Chemically-Designed Dual Inhibitor Of PI3K and HDAC In Patients With Refractory Or Relapsed Lymphoma and Multiple Myeloma

Anas Younes, MD, Ian W. Flinn, MD, PhD, Yasuhiro Oki, MD, Amanda Copland, RN, MSN, CNS, Ali Fattaey, PhD, Cheng-Jung Lai, PhD, Robert Laliberte, MS, Maurizio Voi, MD, Jesus G Berdeja, MD
Journal: Blood
Blood (2013) 122 (21): 4363.
https://doi.org/10.1182/blood.V122.21.4363.4363
Published: 2013